These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7173294)

  • 1. Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers.
    Ibraheem JJ; Paalzow L; Tfelt-Hansen P
    Eur J Clin Pharmacol; 1982; 23(3):235-40. PubMed ID: 7173294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of ergotamine in migraine and cluster headache.
    Perrin VL
    Clin Pharmacokinet; 1985; 10(4):334-52. PubMed ID: 3899452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers.
    Ibraheem JJ; Paalzow L; Tfelt-Hansen P
    Br J Clin Pharmacol; 1983 Dec; 16(6):695-9. PubMed ID: 6419759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic availability of ergotamine tartrate after three successive doses and during continuous medication.
    Ala-Hurula V; Myllylä VV; Arvela P; Kärki NT; Hokkanen E
    Eur J Clin Pharmacol; 1979 Nov; 16(5):355-60. PubMed ID: 520404
    [No Abstract]   [Full Text] [Related]  

  • 5. Intramuscular ergotamine: plasma levels and dynamic activity.
    Tfelt-Hansen P; Paalzow L
    Clin Pharmacol Ther; 1985 Jan; 37(1):29-35. PubMed ID: 3917386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ergotamine in plasma and CSF after i.m. and rectal administration to humans.
    Hovdal H; Syversen GB; Rosenthaler J
    Cephalalgia; 1982 Sep; 2(3):145-50. PubMed ID: 7151147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between pharmacokinetics and clinical effects of ergotamine in patients suffering from migraine.
    Ala-Hurula V
    Eur J Clin Pharmacol; 1982; 21(5):397-402. PubMed ID: 7075645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic availability of ergotamine tartrate after oral, rectal and intramuscular administration.
    Ala-Hurula V; Myllylä VV; Arvela P; Heikkilä J; Kärki N; Hokkanen E
    Eur J Clin Pharmacol; 1979 Feb; 15(1):51-5. PubMed ID: 421728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ergotamine absorption and toxicity.
    Orton DA; Richardson RJ
    Postgrad Med J; 1982 Jan; 58(675):6-11. PubMed ID: 7088766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing.
    Sanders SW; Haering N; Mosberg H; Jaeger H
    Eur J Clin Pharmacol; 1986; 30(3):331-4. PubMed ID: 3732370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low biological availability of ergotamine tartrate after oral dosing in cluster headache.
    Ekbom K; Paalzow L; Waldenlind E
    Cephalalgia; 1981 Dec; 1(4):203-7. PubMed ID: 6812961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic availability of ergotamine tartrate in continuous medication.
    Myllylä VV; Ala-Hurula V; Arvela P; Kärki N; Hokkanen E
    Ups J Med Sci Suppl; 1980; 31():20-2. PubMed ID: 6935854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic availability of ergotamine tartrate in healthy subjects after single and repeated oral doses.
    Ala-Hurula V; Myllylä VV; Arvela P; Kärki NT; Hokkanen E
    Ups J Med Sci Suppl; 1980; 31():7-9. PubMed ID: 6935862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plethysmographic comparison of sublingual and intramuscular ergotamine.
    Winsor T
    Clin Pharmacol Ther; 1981 Jan; 29(1):94-9. PubMed ID: 7460479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ergotamine pharmacokinetics in man: an editorial.
    Eadie MJ
    Cephalalgia; 1983 Sep; 3(3):135-8. PubMed ID: 6627380
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of single dose ergotamine tartrate on peripheral arteries in migraine patients: methodological aspects and time effect curve.
    Tfelt-Hansen P; Eickhoff JH; Olesen J
    Acta Pharmacol Toxicol (Copenh); 1980 Aug; 47(2):151-6. PubMed ID: 7435199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients.
    Hartvig P; Wiklund L; Lindström B
    Acta Anaesthesiol Scand; 1986 Feb; 30(2):177-82. PubMed ID: 3705906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal routes of administration of ergotamine tartrate in cluster headache patients. A pharmacokinetic study.
    Ekbom K; Krabbe AE; Paalzow G; Paalzow L; Tfelt-Hansen P; Waldenlind E
    Cephalalgia; 1983 Mar; 3(1):15-20. PubMed ID: 6406071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans.
    Armer TA; Shrewsbury SB; Newman SP; Pitcairn G; Ramadan N
    Curr Med Res Opin; 2007 Dec; 23(12):3177-87. PubMed ID: 17991308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition of HI-6 oxime in rats after intravenous and intramuscular administration.
    Simons KJ; Briggs CJ
    J Pharm Pharmacol; 1985 May; 37(5):367-9. PubMed ID: 2862253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.